Principal Investigator
Frances Valdes
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230286
Clinical Trial Summary
A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy or tislelizumab in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
+1 (954) 8177628